<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044754</url>
  </required_header>
  <id_info>
    <org_study_id>SALVPROST-YAU-21</org_study_id>
    <nct_id>NCT05044754</nct_id>
  </id_info>
  <brief_title>SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy</brief_title>
  <acronym>SALVPROST</acronym>
  <official_title>Salvage Cryoablation of the Prostate (SCAP) vs High Intensity Focal Ultrasounds (HIFU) for Recurrent Prostate Cancer After Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Universitaire du Cancer - Oncopole. Toulose. France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Virgen de las Nieves</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evidence base relating to the use of SCAP and HIFU is poor, with significant&#xD;
      uncertainties relating to long-term oncological outcomes. One of the main limitations when&#xD;
      the few studies reported are analyzed is the lack of information about the histopathology&#xD;
      both before starting treatment and at the time of recurrence after cryotherapy. The vast&#xD;
      majority of studies refer only to BCR-free survival as end point, thus limiting&#xD;
      interpretation of real oncological performance of this technique. Furthermore, side effects&#xD;
      vary widely from study to study and there are uncertainties about the real morbidity&#xD;
      associated to cryotherapy in the salvage setting.&#xD;
&#xD;
      Another important hot issue in this scenario is the potential benefit that new imaging and&#xD;
      diagnosis techniques (MRI, targeted biopsy, PSMA) may add for a more accurate indication.&#xD;
      This could provide the possibility of better results for SCAP. The clinical value of this new&#xD;
      diagnostic tools is unknown in this scenario and needs to be explored.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>DFS-histology</measure>
    <time_frame>1 year</time_frame>
    <description>Disease free survival (confirmed by follow-up biopsy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS-image</measure>
    <time_frame>1 year</time_frame>
    <description>Disease free survival (confirmed by follow-up PET-CT )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADT-FS</measure>
    <time_frame>5 years</time_frame>
    <description>Androgen deprivation therapy free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCR free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time free of biochemical recurrence (PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFS-PET</measure>
    <time_frame>5 years f-u</time_frame>
    <description>Metastasis free survival. rate of patients without any metastasis detected on PET-CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of early and long-term complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continence</measure>
    <time_frame>1 year</time_frame>
    <description>Change in continence scores (ICIQ-SF q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in sexual function (IIEF questionanaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low urinary tract function</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in IPSS questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cryotherapy</condition>
  <condition>High Intensity Focused Ultrasounds</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SCAP</arm_group_label>
    <description>Patients with recurrent prostate cancer undergoing SCAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIFU</arm_group_label>
    <description>Patients with recurrent prostate cancer undergoing HIFU</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local treatment of the prostate (SCAP or HIFU)</intervention_name>
    <description>Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)</description>
    <arm_group_label>HIFU</arm_group_label>
    <arm_group_label>SCAP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering local recurrence of prostate cancer after primary treatment with&#xD;
        radiation therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with local recurrence (with histological confirmation) after treatment with&#xD;
             radiotherapy or brachytherapy without evidence of distant involvement evaluated&#xD;
             preferably with PET/PSMA (if not available then Fluciclovine PET/CT or choline PET/CT&#xD;
             must be performed).&#xD;
&#xD;
          -  Life expectancy &gt;10 years&#xD;
&#xD;
          -  Prostate volume &lt; 100cc&#xD;
&#xD;
          -  PSA&lt;10 ng/mL&#xD;
&#xD;
          -  mpMRI + fusion/systematic biopsy (template suppl 1) o mpMRI ≤cT3a without affecting&#xD;
             the bladder neck or the membranous urethra so that the continence mechanisms of the&#xD;
             sphincter are not compromised.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically confirmed distant metastasis&#xD;
&#xD;
          -  Any previous major rectal surgery&#xD;
&#xD;
          -  Clinically significant lower urinary tract or rectal anomalies&#xD;
&#xD;
          -  Existing urethral, rectal, or bladder fistulae&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Puche-Sanz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Gomez-Gomez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofia de Cordoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Puche Sanz, MD PhD</last_name>
    <phone>0034 958 02 00 00</phone>
    <email>nacho.puchesanz@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Ploussard, MD PhD</last_name>
      <phone>+33 5 31 15 50 50</phone>
      <email>g.ploussard@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gómez-Gómez</last_name>
      <phone>958 56 76 65</phone>
      <email>enriquegomezgomez@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Enrique Gómez-Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Puche-Sanz</last_name>
      <phone>958 67 56 37</phone>
      <email>nacho.puchesanz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Puche-Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Osman</last_name>
      <phone>+0034 955 01 20 00</phone>
      <email>nachosman79@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Virgen de las Nieves</investigator_affiliation>
    <investigator_full_name>Ignacio Puche Sanz</investigator_full_name>
    <investigator_title>MD PhD Urologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

